Navigation Links
Amicus Therapeutics to Host its First Quarter 2010 Financial Results Conference Call and Webcast on May 6, 2010
Date:4/28/2010

CRANBURY, N.J., April 28 /PRNewswire-FirstCall/ -- Amicus Therapeutics (Nasdaq: FOLD) will release its first quarter 2010 financial results after the regular close of markets on Thursday, May 6, 2010. The results announcement will be followed by a live conference call and webcast that afternoon at 5 p.m. EDT.

Interested participants and investors may access the conference call at 5 p.m. EDT by dialing 877-303-5859 (U.S./Canada) or 678-224-7784 (international). A telephonic replay of the call will be available for seven days beginning at 8 p.m. EDT. Access numbers for this replay are 800-642-1687 (U.S./Canada) and 706-645-9291 (international); participant code 70672340.

An audio webcast can also be accessed via the investor section of the Amicus Therapeutics Web site at www.amicustherapeutics.com under Investors: Events and Presentations. Web participants are encouraged to go to the Web site 15 minutes prior to the start of the call to register, download and install any necessary software. After the live webcast, an audio webcast replay will remain available in the Investors section of the Amicus Therapeutics Web site for 30 days.

Amicus' press releases are available at www.amicustherapeutics.com.  

About Amicus Therapeutics

Amicus Therapeutics is developing orally-administered, small molecule drugs called pharmacological chaperones, a novel, first-in-class approach to treating a broad range of diseases including lysosomal storage disorders and diseases of neurodegeneration.  Amicus' lead program is in Phase 3 for the treatment of Fabry disease. 

FOLD –G


'/>"/>
SOURCE Amicus Therapeutics
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. FDA Clears the Fenwal Amicus(R) Separator System for Collecting Platelets in New Additive Solution
2. Amicus Therapeutics Announces Closing of $18.5 Million Registered Direct Offering of Common Stock
3. Amicus Therapeutics Announces $18.5 Million Registered Direct Offering of Common Stock
4. Amicus Therapeutics Announces Fourth Quarter and Full Year 2009 Financial Results and Highlights Product Pipeline Advancements
5. Amicus Therapeutics Presents Positive Data Update From Phase 2 Extension Study of Amigal(TM) for Fabry Disease
6. Amicus Therapeutics Commences Phase 3 Trial Evaluating Amigal(TM) for the Treatment of Fabry Disease
7. Amicus Therapeutics Announces Issuance of New Plicera(TM) Composition of Matter Patent
8. Amicus Therapeutics Suspends Enrollment for Phase 2 Clinical Trial of AT2220 for Pompe Disease
9. Amicus Therapeutics Announces Positive Progress of Three Lead Clinical Programs and General Outlook for 2009
10. Amicus Therapeutics Announces Second Quarter 2008 Financial Results
11. Amicus Therapeutics Announces Successful Completion of End of Phase 2 Meeting With FDA for Amigal in Fabry Disease
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/23/2017)... -- The global  anxiety disorders and depression treatment market  is expected ... of depression worldwide is anticipated to drive the market growth in the coming ... for antidepressants in the recent years. Continue Reading ... ... ...
(Date:1/23/2017)... , Jan 23, 2017 NeuroVive Pharmaceutical ... has signed a preclinical collaboration agreement with the Children,s Hospital ... J. Falk , M.D., a US key opinion leader in ... ... will evaluate compounds from NeuroVive,s research program, NVP015, in certain ...
(Date:1/21/2017)... Research and Markets has announced the ... Type of Test (Tumor, Clinical Chemistry, Microbiology, Esoteric), By Type ... (Tuberculosis, Influenza, Cancer, HIV/AIDS etc.), Forecast to 2022" report ... ... market segments, especially clinical lab testing, which has evolved as ...
Breaking Medicine Technology:
(Date:1/23/2017)... ... January 23, 2017 , ... ... institution’s inaugural K-20 Education Summit to be held March 23-25, 2017 in Tampa, ... Jan. 25, 2017. , The keynote speakers include Dr. Michelle R. Weise, executive ...
(Date:1/23/2017)... ... January 23, 2017 , ... Sharon Kleyne, America’s leading water researcher, advocate and ... the benefits of making new water infrastructure a number one priority. “As we usher ... expect water infrastructure to become a top priority of our new political change agents.” ...
(Date:1/23/2017)... ... January 23, 2017 , ... ... has earned organic certification under the USDA National Organic Program (NOP) for its ... process, we have established organic production and handling systems to complement our current ...
(Date:1/23/2017)... ... January 23, 2017 , ... “The Inn at the Mill”: a story of love and ... quest to become happy and content. , “The Inn at the Mill” is the ... in Germany and Vermont and is now living in Berks County on Crow Hill. ...
(Date:1/23/2017)... ... ... a time when many people celebrate romance and love by giving cards, candy, flowers or ... present, Atlanta-based Perimeter Plastic Surgery is offering a Valentine’s Day special: Spend $100 ... $50 free. , “A lot of people just buy the more predictable gift of ...
Breaking Medicine News(10 mins):